Kyoko Shirota
About
In The Last Decade
Kyoko Shirota
23 papers receiving 416 citations
Peers
Comparison fields: 5 of 62
- Reproductive Medicine 193
- Public Health, Environmental and Occupational Health 175
- Molecular Biology 109
- Obstetrics and Gynecology 71
- Oncology 68
Countries citing papers authored by Kyoko Shirota
This map shows the geographic impact of Kyoko Shirota's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyoko Shirota with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyoko Shirota more than expected).
Fields of papers citing papers by Kyoko Shirota
This network shows the impact of papers produced by Kyoko Shirota. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyoko Shirota. The network helps show where Kyoko Shirota may publish in the future.
Co-authorship network of co-authors of Kyoko Shirota
This figure shows the co-authorship network connecting the top 25 collaborators of Kyoko Shirota. A scholar is included among the top collaborators of Kyoko Shirota based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyoko Shirota. Kyoko Shirota is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 86 | |
| 3 | 9 | |
| 4 | 5 | |
| 5 | 19 | |
| 6 | 1 | |
| 7 | Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA. | 5 |
| 8 | Emerging strategies for ErbB ligand-based targeted therapy for cancer. | 16 |
| 9 | HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer. | 22 |
| 10 | Apoptosis as a possible candidate mechanism for removal of tamoxifen-related endometrial cells with KRAS mutations. | 1 |
| 11 | 4 | |
| 12 | 24 | |
| 13 | Efficacy of ligand-based targeting for the EGF system in cancer. | 26 |
| 14 | 42 | |
| 15 | 37 | |
| 16 | 1 | |
| 17 | 11 | |
| 18 | 23 | |
| 19 | 23 | |
| 20 | 6 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.